CD274 and non-small cell lung carcinoma: On the other hand, given that there is no significant clinical benefit of ICI monotherapy for patients with advanced/metastatic NSCLC with low or no PD-L1 expression, it is hoped that adagrasib alone or in combination will improve outcomes.